Skip to main content

Table 1 Sociodemographic and laboratory information of ESLD and Chronic HBV patients

From: Ambulatory end-stage liver disease in Ghana; patient profile and utility of alpha fetoprotein and aspartate aminotransferase: platelet ratio index

  HCC
n/N* (%)
Cirrhosis
n/N* (%)
Chronic HBV n/N* (%)
Sociodemographic information
 Sex
  Men 106/139 (76.3) 150/214 (70.1) 125/218 (57.3)
  Women 33/139 (23.7) 64/214 (29.9) 92/218 (42.2)
 Age at diagnosis, median (IQR)
  Overall 44 (36–54) 46 (37–46) 35 (28–44)
  HBV 43 (36–48) 42 (34–50)
  HCV 53 (47–65) 49 (40.5–59.5)
  ALD 42 (39–50) 51 (44–60)
 Monthly household income in Ghana cedis, (GHS) with USD ($) equivalent
  < 500 ($90) 44/100 (44.0) 91/151 (60.3) 88/165 (53.3)
  500–999 ($91–182) 29/100 (29.0) 24/151 (15.9) 39/165 (23.6)
  1000–2499 ($182–454) 24/100 (24.0) 27/151 (17.9) 32/165 (19.4)
  > 2500 (> $454) 3/100 (3.0) 9/151 (6.0) 6/165 (3.6)
Laboratory information
 Platelet, mean (SD) 224.9 (150) 141.3 (104) 221.1 (59)
 Prothrombin time INR, mean (SD) 1.3 (0.7) 1.8 (1.3)
 Albumin (g/L), mean (SD) 35.1 (11.9) 30.8 (9.9) 42.0 (7.0)
 APRI score, median (IQR) 1.5 (0.7–2.9) 1.4 (0.7–3.0) 0.3 (0.3–0.5)
 AFP (ng/mL), median (IQR) 528.1 (31.45–3149) 4.6 (2.6–8.7)
 HBV DNA (IU/mL), median (IQR) 21,615 (8580–122,500) 1903.5 (20–76,399) 3503 (489–15,300)
  1. n/N* The total number of patients was 141 HCC, 216 liver cirrhosis and 218 chronic HBV, however not all questions were answered by all participants
  2. Missing laboratory data: Platelet count (HCC 36, cirrhosis 50, and chronic HBV 117); INR (HCC 59 and cirrhosis 103); Albumin (HCC 33, cirrhosis 47, and chronic HBV 99); AFP (HCC 80 and cirrhosis 147); HBV DNA (HCC 86, cirrhosis 89, and HBV 132)